Patients with COVID-19 have varied risk for increasing severity of disease, with the chance of progression and mortality being higher in older patients and those with comorbidities. Monoclonal antibody therapies that prevent the need for hospitalization in high-risk outpatients who have COVID-19 have been given Emergency Use Authorization by the FDA. These agents include a cocktail consisting of casirivimab and imdevimab and a cocktail of bamlanivimab and etesevimab.
This activity High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression will provide clinicians who manage outpatients with COVID-19 with a review of the most current management guidelines and information on the mechanism of action, efficacy and safety data, and patient eligibility for the monoclonal antibodies that have received emergency use authorization (EUA) by the FDA to treat outpatients with COVID-19.
Peter Chen, MD
Professor of Medicine and Biomedical Sciences
Director, Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
Raymund R. Razonable, MD
Professor of Medicine
Jointly provided by the Potomac Center for Medical Education and Rockpointe
Education resources provided in collaboration with
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.